A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 2, 2013, Pages 231-239

  Bailey, Lucy ^a   Moreno, Laura ^a   Manigold, Tobias ^b,d   Krasniqi, Sebastian ^b   Kropshofer, Harald ^b   Hinton, Heather ^b   Singer, Thomas ^b   Suter, Laura ^b   Hansel, Trevor T ^c   Mitchell, Jane A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biotherapeutics; Cytokine storm; Methods; Whole blood assay

Indexed keywords

ALEMTUZUMAB; CETUXIMAB; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TGN 1412; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOASSAY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; VOLUNTEER;

BIOTHERAPEUTICS; CYTOKINE STORM; METHODS; WHOLE BLOOD ASSAY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, NEOPLASM; BIOLOGICAL ASSAY; COCULTURE TECHNIQUES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84882866294     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.12.003     Document Type: Article

References (19)

1. Cartwright N., Murch O., McMaster S.K., Paul-Clark M.J., van Heel D.A., Ryffel B., et al. Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. [Research Support, Non-U.S. Gov't]. American Journal of Respiratory and Critical Care Medicine 2007, 175(6):595-603.
2. Eastwood D., Findlay L., Poole S., Bird C., Wadhwa M., Moore M., et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. British Journal of Pharmacology 2010, 161(3):512-526.
3. Findlay L., Eastwood D., Stebbings R., Sharp G., Mistry Y., Ball C., et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. Journal of Immunological Methods 2010, 352(1-2):1-12.
4. Findlay L., Sharp G., Fox B., Ball C., Robinson C.J., Bird C., et al. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine 2011, 55(1):141-151.
5. George T.J., Laplant K.D., Walden E.O., Davis A.B., Riggs C.E., Close J.L., et al. Managing cetuximab hypersensitivity-infusion reactions: Incidence, risk factors, prevention, and retreatment. The Journal of Supportive Oncology 2010, 8(2):72-77.
6. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J. The safety and side effects of monoclonal antibodies. Nature Reviews. Drug Discovery 2010, 9(4):325-338. (Review).
7. Lowe P.J., Tannenbaum S., Wu K., Lloyd P., Sims J. On setting the first dose in man: Quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic & Clinical Pharmacology & Toxicology 2010, 106(3):195-209.
8. Lowry S.F. Human endotoxemia: A model for mechanistic insight and therapeutic targeting. [Research Support, N.I.H., Extramural Review]. Shock 2005, 24(Suppl. 1):94-100.
9. Mitchell J.A., Lucas R., Vojnovic I., Hasan K., Pepper J.R., Warner T.D. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. [Research Support, Non-U.S. Gov't]. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2006, 20(14):2468-2475.
10. Nicholson G.M.L., Wheeler-Jones C., Singer T., Kropshofer H., Hansel T., Mitchell J.A. Importance of endothelial cell-leukocyte interactions in the sensing of TLR4 and NOD1 ligands by peripheral blood mononuclear cells in vitro. PA2 online, 078P 2009.
11. Paul-Clark M.J., Sorrentino R., Bailey L.K., Sriskandan S., Mitchell J.A. Gram-positive and Gram-negative bacteria synergize with oxidants to release CXCL8 from innate immune cells. [Research Support, Non-U.S. Gov't]. Molecular Medicine 2008, 14(5-6):238-246.
12. Sandilands G.P., Wilson M., Huser C., Jolly L., Sands W.A., McSharry C. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?. Clinical and Experimental Immunology 2010, 162(3):516-527.
13. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics. Journal of Immunology 2007, 179(5):3325-3331.
14. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. [Clinical Trial, Phase I Randomized Controlled Trial]. The New England Journal of Medicine 2006, 355(10):1018-1028.
15. Walker M.R., Makropoulos D.A., Achuthanandam R., Van Arsdell S., Bugelski P.J. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis. International Immunopharmacology 2011, 11(11):1697-1705.
16. Ward J.R., Francis S.E., Marsden L., Suddason T., Lord G.M., Dower S.K., et al. A central role for monocytes in toll-like receptor-mediated activation of the vasculature. [Research Support, Non-U.S. Gov't]. Immunology 2009, 128(1):58-68.
17. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. [Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(13):7563-7568.
18. Wing M.G., Waldmann H., Isaacs J., Compston D.A., Hale G. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: Dependence on target antigen and antibody isotype. [Comparative Study Research Support, Non-U.S. Gov't]. Therapeutic Immunology 1995, 2(4):183-190.
19. Wolf B., Morgan H., Krieg J., Gani Z., Milicov A., Warncke M., et al. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. Cytokine 2012, 60(3):828-837.